Jack Meehan
Stock Analyst at Barclays
(3.05)
# 1,379
Out of 5,005 analysts
137
Total ratings
69.51%
Success rate
21.33%
Average return
Main Sectors:
Stocks Rated by Jack Meehan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LH Labcorp Holdings | Maintains: Equal-Weight | $275 → $290 | $276.94 | +4.72% | 17 | Oct 2, 2025 | |
| A Agilent Technologies | Maintains: Underweight | $120 → $125 | $141.64 | -11.75% | 20 | Feb 28, 2024 | |
| WAT Waters | Maintains: Equal-Weight | $275 → $288 | $328.39 | -12.30% | 10 | Aug 3, 2023 | |
| AVTR Avantor | Initiates: Overweight | $33 | $14.29 | +130.93% | 3 | Mar 3, 2021 | |
| ILMN Illumina | Initiates: Underweight | $325 | $102.12 | +218.25% | 8 | Mar 3, 2021 | |
| INMD InMode | Maintains: Overweight | $18 → $19 | $15.15 | +25.41% | 3 | Aug 17, 2020 | |
| DGX Quest Diagnostics | Maintains: Equal-Weight | $93 → $99 | $179.33 | -44.79% | 7 | Apr 23, 2020 | |
| ICLR ICON Public Limited Company | Maintains: Overweight | $170 → $180 | $193.89 | -7.16% | 2 | Apr 23, 2020 | |
| MYGN Myriad Genetics | Maintains: Underweight | $14 → $10 | $8.06 | +24.07% | 8 | Mar 26, 2020 | |
| IQV IQVIA Holdings | Maintains: Overweight | $192 → $166 | $206.63 | -19.66% | 4 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $51 → $43 | $68.22 | -36.97% | 9 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $154 | $177.33 | -13.16% | 7 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $430 | $305.49 | +40.76% | 6 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $430 | $303.30 | +41.77% | 6 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | n/a | $29.98 | - | 10 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $52 → $48 | $36.98 | +29.80% | 4 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $720 → $680 | $1,314.04 | -48.25% | 4 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $30 | $94.95 | -68.40% | 3 | Oct 2, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $295 → $300 | $543.32 | -44.78% | 5 | Mar 18, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $40 | $1.62 | +2,369.14% | 1 | Dec 11, 2017 |
Labcorp Holdings
Oct 2, 2025
Maintains: Equal-Weight
Price Target: $275 → $290
Current: $276.94
Upside: +4.72%
Agilent Technologies
Feb 28, 2024
Maintains: Underweight
Price Target: $120 → $125
Current: $141.64
Upside: -11.75%
Waters
Aug 3, 2023
Maintains: Equal-Weight
Price Target: $275 → $288
Current: $328.39
Upside: -12.30%
Avantor
Mar 3, 2021
Initiates: Overweight
Price Target: $33
Current: $14.29
Upside: +130.93%
Illumina
Mar 3, 2021
Initiates: Underweight
Price Target: $325
Current: $102.12
Upside: +218.25%
InMode
Aug 17, 2020
Maintains: Overweight
Price Target: $18 → $19
Current: $15.15
Upside: +25.41%
Quest Diagnostics
Apr 23, 2020
Maintains: Equal-Weight
Price Target: $93 → $99
Current: $179.33
Upside: -44.79%
ICON Public Limited Company
Apr 23, 2020
Maintains: Overweight
Price Target: $170 → $180
Current: $193.89
Upside: -7.16%
Myriad Genetics
Mar 26, 2020
Maintains: Underweight
Price Target: $14 → $10
Current: $8.06
Upside: +24.07%
IQVIA Holdings
Mar 26, 2020
Maintains: Overweight
Price Target: $192 → $166
Current: $206.63
Upside: -19.66%
Mar 26, 2020
Maintains: Equal-Weight
Price Target: $51 → $43
Current: $68.22
Upside: -36.97%
Mar 26, 2020
Maintains: Equal-Weight
Price Target: $170 → $154
Current: $177.33
Upside: -13.16%
Mar 26, 2020
Maintains: Overweight
Price Target: $435 → $430
Current: $305.49
Upside: +40.76%
Mar 26, 2020
Maintains: Overweight
Price Target: $435 → $430
Current: $303.30
Upside: +41.77%
Mar 26, 2020
Downgrades: Equal-Weight
Price Target: n/a
Current: $29.98
Upside: -
Mar 26, 2020
Upgrades: Overweight
Price Target: $52 → $48
Current: $36.98
Upside: +29.80%
Mar 26, 2020
Upgrades: Equal-Weight
Price Target: $720 → $680
Current: $1,314.04
Upside: -48.25%
Oct 2, 2019
Maintains: Underweight
Price Target: $28 → $30
Current: $94.95
Upside: -68.40%
Mar 18, 2019
Maintains: Overweight
Price Target: $295 → $300
Current: $543.32
Upside: -44.78%
Dec 11, 2017
Initiates: Equal-Weight
Price Target: $40
Current: $1.62
Upside: +2,369.14%